Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 2:15:1384002.
doi: 10.3389/fimmu.2024.1384002. eCollection 2024.

Effectiveness of CAR-T treatment toward the potential risk of second malignancies

Massimo Martino  1   2 , Gaetana Porto  1   2 , Giorgia Policastro  1   2 , Caterina Alati  2   3 , Barbara Loteta  1   2 , Maria Caterina Micó  1   2 , Clizia Argiró  1   2 , Maria Altomonte  2   4 , Tiziana Moscato  1   2 , Demetrio Labate  2   5 , Vincenzo Dattola  2   6 , Carmelo Massimiliano Rao  2   7 , Francesca Cogliandro  1   2 , Filippo Antonio Canale  1   2 , Virginia Naso  1   2 , Gianfranco Filippelli  8 , Antonino Iaria  9 , Martina Pitea  1   2
Affiliations

Effectiveness of CAR-T treatment toward the potential risk of second malignancies

Massimo Martino et al. Front Immunol. .
No abstract available

Keywords: car-t; follow-up; malignancies; second cancer; therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

References

    1. Joy R, Phair K, O'Hara R, Brady D. Recentadvances and current challenges in CAR-T cell therapy. Biotechnol Lett. (2024) 46:115–26. doi: 10.1007/s10529-023-03461-0 - DOI - PubMed
    1. Abbasi S, Totmaj MA, Abbasi M, Hajazimian S, Goleij P, Behroozi J, et al. . (CAR-T) cells: Novelcell therapy for hematologicalmalignancies. Cancer Med. (2023) 12:7844–58. doi: 10.1002/cam4.5551 - DOI - PMC - PubMed
    1. Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione CA. Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute LymphoblasticLeukemia. Int J Mol Sci. (2021) 22:2150. doi: 10.3390/ijms22042150 - DOI - PMC - PubMed
    1. Martino M, Canale FA, Naso V, Porto G, Gerace D, Allegra A. Do CAR-T and AllogeneicStem Cell TransplantBothHave a Place in LymphoidNeoplasms? Int J Mol Sci. (2023) 24:1045. doi: 10.3390/ijms24021045 - DOI - PMC - PubMed
    1. Martino M, Canale FA, Porto G, Verduci C, Utano G, Policastro G, et al. . Integrating CAR-T cell therapy into the management of DLBCL: whatwe are learning. Expert OpinBiolTher. (2023) 23:1277–85. doi: 10.1080/14712598.2023.2292634 - DOI - PubMed

MeSH terms

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

LinkOut - more resources